Callitas Theraputics Inc., a wholly owned subsidiary of Callitas Health Inc.

lthompson

About Lindsey Thompson

This author has not yet filled in any details.
So far Lindsey Thompson has created 39 blog entries.

Callitas Provides Third Default Status Report

2019-06-12T15:50:47-05:00

CINCINNATI, OH – June 12, 2019 – Callitas Health Inc. ("Callitas" or the "Company") (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) provides its third bi-weekly Default Status Report under National Policy 12-203 Management Cease Trade Orders("NP 12-203"), pursuant to which Callitas issued its original default announcement indicating that the filing of its annual audited financial statements, [...]

Callitas Provides Third Default Status Report2019-06-12T15:50:47-05:00

Callitas Provides Second Default Status Report

2019-05-30T18:25:12-05:00

CINCINNATI, OH – May 29, 2019 –  Callitas Health Inc. ("Callitas" or the "Company")  (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) provides its second bi-weekly Default Status Report under National Policy 12-203 Management Cease Trade Orders("NP 12-203"), pursuant to which Callitas issued its original default announcement indicating that the filing of its annual audited financial [...]

Callitas Provides Second Default Status Report2019-05-30T18:25:12-05:00

Callitas Health Welcomes Brian D. Keane as Capital Markets and Merger and Acquisitions Consultant

2019-05-23T19:14:11-05:00

CINCINNATI, OH, May 28, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that Brian D. Keane will join the team as the Company’s Capital Markets and Merger and Acquisitions Consultant. The addition [...]

Callitas Health Welcomes Brian D. Keane as Capital Markets and Merger and Acquisitions Consultant2019-05-23T19:14:11-05:00

Callitas Health, Inc. Announces Closing of Private Placements

2019-05-23T19:12:06-05:00

CINCINNATI, OH, May 22, 2019– Callitas Health Inc.(CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced it has completed its recently announced non-brokered private placement. The Company issued 3,856,333 units at a price of $0.075 per unit, for gross proceeds of [...]

Callitas Health, Inc. Announces Closing of Private Placements2019-05-23T19:12:06-05:00

Callitas Provides Status Update

2019-05-15T21:43:12-05:00

CINCINNATI, OH – May 15, 2019 –  Callitas Health Inc. ("Callitas" or the "Company")  (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) announces that further to its news release dated May 1, 2019, the Company’s principal regulator, the British Columbia Securities Commission (the "BCSC") granted a management cease trade order (the "MCTO") on May 1, 2019, [...]

Callitas Provides Status Update2019-05-15T21:43:12-05:00

Callitas Health Announces Late Filing of Annual Financial Disclosure

2019-04-30T20:14:12-05:00

CINCINNATI, OH – May 1, 2019 –  Callitas Health Inc. ("Callitas" or the "Company")  (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) today announced that the filing of its audited annual financial statements, management's discussion and analysis and related CEO and CFO certifications for the financial year ended December 31, 2018 (the "Required Filings"), will be [...]

Callitas Health Announces Late Filing of Annual Financial Disclosure2019-04-30T20:14:12-05:00

Callitas Health Announces Notice of Allowance for a Biphasic Oral Cannabinoid Patent by U.S. Patent Office, Next Evolution of Cannabis Delivery

2019-04-28T20:39:30-05:00

CINCINNATI, OH, April 25, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods sales & marketing and cannabis delivery development company, today announced its  Notice of Allowance for U.S Application Serial Number 16/350,351 from the U.S. Patent and Trademark Office (USPTO) [...]

Callitas Health Announces Notice of Allowance for a Biphasic Oral Cannabinoid Patent by U.S. Patent Office, Next Evolution of Cannabis Delivery2019-04-28T20:39:30-05:00

Callitas Health Signs Letter of Intent with Simply Wholeistic, LLC to Supply Cannastrip Technology and Dietary Supplements Nationwide

2019-04-18T17:48:13-05:00

CINCINNATI, OH, April 19, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) announced today that it has signed a letter of intent with Simply Wholeistic to manufacture and supply formulations of CannaStrip and other Simply Wholistic dietary supplement products for retail sale in the United States. Since [...]

Callitas Health Signs Letter of Intent with Simply Wholeistic, LLC to Supply Cannastrip Technology and Dietary Supplements Nationwide2019-04-18T17:48:13-05:00

Callitas Health Announces the Promotion of Joshua Maurice to Vice President of Sales and Business Development

2019-03-13T21:08:14-05:00

CINCINNATI, OH, March 12, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that Joshua Maurice has been promoted to vice president of sales and business development for Callitas, effective March 12, 2019. [...]

Callitas Health Announces the Promotion of Joshua Maurice to Vice President of Sales and Business Development2019-03-13T21:08:14-05:00

Callitas Health Expands Agreement with NFI Consumer Healthcare to Distribute Co-Branded Product

2019-02-26T17:26:43-05:00

CINCINNATI, OH, February 26, 2019 – Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, announced today that it has amended and expanded its original agreement with NFI Consumer Healthcare. The new agreement includes distribution of [...]

Callitas Health Expands Agreement with NFI Consumer Healthcare to Distribute Co-Branded Product2019-02-26T17:26:43-05:00